The current study evaluated the impact of the Oncotype DX recurrence score (RS) on the patterns of locoregional recurrence (LRR) in node-negative, hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Totally, 339 patients from 4 institutions were enrolled and analyzed retrospectively. All patients underwent breast-conserving surgery followed by whole-breast irradiation; only 2 patients received regional nodal irradiation (RNI). The RS was < 11 in 55 patients, 11 –25 in 241, and > 25 in 43. Sixty-two patients received adjuvant chemotherapy. All patients except 4 received hormonal therapy. During a 62-month median follow-up, local recurrence was observed in 1 patient; regional recurrence, 3; and distant metastasis, 7. All LRRs were observed among patients with a RS > 25, resulting in a 5-year LRR rate of 7.3% in this subgroup. Regional recurrences developed in patients did not receive RNI initially. Thus, RNI might be effective for patients with a high RS.

Keywords: Breast neoplasm; Local neoplasm recurrence; Radiotherapy

As two randomized trials showed the benefit of regional nodal irradiation for early breast cancer [1,2], comprehensive regional radiotherapy (RT) has been recommended for patients with node-positive breast cancer. In contrast, 15% of the study population was node-negative in the Canadian randomized trial [1] and 44% in the European randomized trial [2]. In particular, in the latter study, the disease-free survival rate improved after regional RT, regardless of nodal involvement [2]. On the basis of these findings, the National Comprehensive Cancer Network guidelines recommend that regional RT should be considered even for node-negative patients with central/medial tumors or for patients with tumors > 2 cm with risk factors such as young age or extensive lymphovascular invasion [3].
On evaluating the impact of breast RT after breast-conserving surgery (BCS) for node-negative disease, the Early Breast Cancer Trialists’ Collaborative Group observed that the reduction of first recurrence after breast RT was consistent in most subgroups classified by age, grade, tumor size, and hormonal receptor status [4]. More recently, however, genomic biomarkers are increasingly being investigated to select patients who will most benefit from breast RT [5,6]. Among the various genomic biomarkers, the Oncotype DX recurrence score (RS) is the most popular biomarker for patients with node-negative, hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. While the RS was initially known to be associated with distant metastasis [7], subsequent studies showed that it also predicts locoregional recurrence (LRR) [8-10]. However, only a few studies have investigated whether the RS is associated with regional recurrence alone and whether it can be used for selecting a subgroup of patients who will benefit from regional RT.

Therefore, the current study aimed to evaluate the impact of the Oncotype DX RS on the patterns of LRR in patients who underwent BCS and postoperative RT for node-negative, hormone receptor-positive/HER2-negative breast cancer.

The medical records of 401 patients who underwent RT after BCS for node-negative, hormonal receptor-positive/HER2-negative breast cancer between January 2010 and December 2015 and whose Oncotype DX RS was available were retrospectively reviewed. After excluding 62 patients whose RT field data were unavailable, a total of 339 patient from 4 institutions were included in this study. The institutional review board approved this study (H-1909-024-1060) and waived the requirement for informed consent.

All the patients underwent BCS and sentinel lymph node (LN) biopsy, or BCS and axillary LN dissection. None of them received neoadjuvant systemic therapy. After Oncotype DX testing, systemic therapy was performed at the treating physician’s discretion. If a chemotherapy regimen—apart from the cyclophosphamide, methotrexate, and 5-fluorouracil regimen (which was administered concomitantly with RT)—was offered, postoperative RT was administered after the completion of chemotherapy. All the patients received whole-breast RT, and only 2 patients received regional RT to the supraclavicular fossa. A total of 302 patients received conventional fractionated RT (50–50.4 Gy in 25–28 fractions) and 37 received hypofractionated RT (39–43.2 Gy in 13–16 fractions). Tumor bed boost was performed for all patients, except 1.

We evaluated local, regional, and distant recurrences. Recurrences in the ipsilateral breast were defined as local recurrences, and those in the ipsilateral axillary, supraclavicular, and/or internal mammary LNs as regional recurrences. Distant recurrences indicated tumor recurrences outside the regions identified as locoregional sites. The SPSS software (release 18.0.1. SPSS Inc., Chicago, USA) was used for statistical analysis.

The median age of all the patients was 47 years (range, 29–77 years). A total of 164 patients had right breast cancer and 175 had left breast cancer. Regarding the tumor location, 119 patients had inner tumors, 170 had outer tumors, and 49 had central tumors. One patient had multicentric tumors. Two hundred ninety-nine patients had invasive ductal carcinomas (88.2%). The pathologic tumor size ranged from 0.4 cm to 5.5 cm (median, 1.6 cm). Totally, 233 patients (68.7%) had T1 tumors while 105 (31.0%) had T2 tumors. Only 1 patient had a T3 tumor. The histologic grade was 3 in 57 patients (16.8%), and lymphovascular invasion was observed in 74 patients (21.8%). The patient and tumor characteristics are summarized in Table 1.
The Oncotype DX RS ranged from 0 to 71 (median, 17). The RS was < 11 in 55 patients (16.2%), 11–25 in 241 patients (71.1%), and >25 in 43 patients (12.7%). Of the 296 patients, 24 patients (8.1%) with a RS ≤ 25 received chemotherapy. Among the 43 patients with a RS > 25, 5 patients (11.6%) did not receive chemotherapy.

A total of 62 patients received systemic chemotherapy. The chemotherapeutic regimens were doxorubicin and cyclophosphamide in 28 patients; 5-fluorouracil, doxorubicin and cyclophosphamide in 23; docetaxel and cyclophosphamide in 6; cyclophosphamide, methotrexate, and 5-fluorouracil in 4; doxorubicin and cyclophosphamide followed by paclitaxel in 1. All the patients underwent hormonal therapy, except for 4 patients who wanted to get pregnant in future. A total of 265 patients received tamoxifen, 62 received an aromatase inhibitor, and 8 received tamoxifen initially and switched to an aromatase inhibitor.

The median duration of follow-up was 62 months (range, 17–109 months). Local recurrence was observed in 1 patient, regional recurrence in 3 patients, and distant metastasis in 7
patients. All the cases of LRR were observed among those patients with a RS > 25, resulting in a 5-year LRR rate of 7.3% in this subgroup. The regional recurrence sites were the axillary LNs in 2 patients and the supraclavicular LN in 1 patient, none of whom had received regional RT initially. The detailed summary of recurrences is shown in Table 2.

The current study analyzed the outcomes of BCS plus RT for node-negative, hormonal receptor-positive/HER2-negative breast cancer according to the Oncotype DX RS. LRR was observed in only 4 patients, all of whom had a RS > 25. In addition, patients with regional recurrences did not receive regional RT initially.

The Oncotype DX RS is well known to be associated with distant metastasis [7], and the correlation with LRR has been reported in several studies [8,9]. For example, in the combined analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 and B-20 trials, the 10-year LRR rates of the low (< 18), intermediate (18–30), and high RS (> 30) groups were 4.3%, 7.2%, and 15.8%, respectively (p < 0.0001), in patients receiving tamoxifen [8]. In those patients receiving chemotherapy and tamoxifen, the corresponding values were 1.6%, 2.7%, and 7.8%, respectively (p = 0.028). Moreover, Turashvili et al. [9] from the Memorial Sloan Kettering Cancer Center observed that the 4-year LRR rates of the low, intermediate, and high RS groups were 0.84%, 2.72%, and 2.80%, respectively (p < 0.01). Although these studies suggest that the LRR rate was significantly separated by using the RS, the differences in the local and systemic treatments as well as the follow-up duration should be considered in the interpretation. In addition, the risk factors other than RS should be considered. Moreover, age, type of surgery [8], T stage, and lymphovascular invasion [9] were additional prognostic factors for LRR in the multivariate analyses performed in the aforementioned studies. In the current study, we adopted a cutoff value of 25 for the RS from the TAILORx trial [11]. All the patients underwent BCS and RT, and 88% of patients with a RS > 25 received chemotherapy. Although risk factor analysis could not be performed owing to the small number of events, all the 4 cases of LRR were observed in patients with a high RS, consistent with the observations in previous studies.

Considering the correlation between the RS and LRR, many studies are underway to guide the optimal indications of RT. Most of these studies are focusing on the necessity of post-mastectomy RT for patients with pT1-2N1 breast cancer [12,13] or the omission of whole-breast RT after BCS for patients with a low RS [14,15]. Meanwhile, only a few studies are

### Table 2. Summary of recurrences

| Recurrence          | Age (yr) | Tumor size (cm) | Histologic grade | Lymphovascular invasion | Resection margin | Recurrence score | Chemotherapy | Hormonal therapy | Time to recurrence |
|---------------------|----------|-----------------|------------------|-------------------------|------------------|------------------|--------------|------------------|-------------------|
| Local†              | 37       | 1.5             | III              | No                      | Negative         | 49               | AC #4        | Tamoxifen         | 37 mon            |
| Regional (axillary LN) | 61       | 1.3             | II               | No                      | Negative         | 30               | FAC #6       | AI               | 20 mon            |
| Regional (supraclavicular LN)† | 56       | 1.6             | II               | Yes                     | Negative         | 28               | AC #4        | Tamoxifen         | 49 mon            |
| Regional (axillary LN)* | 37      | 1.5             | III              | No                      | Negative         | 49               | AC #4        | Tamoxifen         | 51 mon            |
| Distant (lung)      | 40       | 2               | III              | Yes                     | Negative         | 29               | FAC #6       | Tamoxifen         | 19 mon            |
| Distant (mediastinal LN & bone) | 49 | 2               | III              | No                      | Negative         | 24               | No           | Tamoxifen         | 21 mon            |
| Distant (liver)     | 61       | 2.4             | III              | No                      | Negative         | 12               | No           | Tamoxifen         | 7 mon             |
| Distant (bone)      | 32       | 3.1             | III              | No                      | Negative         | 22               | AC #4        | Tamoxifen         | 70 mon            |
| Distant (lung)*     | 37       | 1.5             | III              | No                      | Negative         | 49               | AC #4        | Tamoxifen         | 51 mon            |
| Distant (bone)      | 49       | 2.5             | II               | Yes                     | Negative         | 15               | No           | Tamoxifen         | 58 mon            |

LN = lymph node; AC = doxorubicin and cyclophosphamide; FAC = 5-fluorouracil, doxorubicin and cyclophosphamide; AI = aromatase inhibitor.

*This patient experienced local recurrence first, and subsequently regional and distant recurrences 14 months later; †This patient experienced simultaneous regional and distant recurrences.
investigating whether the RS is associated with regional recurrence alone and if it can be used to select the subgroup of patients who will benefit from regional RT. Mamounas et al. [16] analyzed the correlation between the RS and LRR in a subgroup of the NSABP B-28 trial, in which all patients were treated with chemotherapy and hormonal therapy. Among patients with 1–3 positive LNs who underwent BCS + RT, the 10-year regional recurrence rates of the low, intermediate, and high RS groups were 0%, 0%, and 3.5%, respectively. Even in patients with ≥ 4 positive LNs, the corresponding values were as low as 0%, 2%, and 0%, respectively. Regional recurrences were also rare in the aforementioned studies involving node-negative patients. In the NSABP B-14 and B-20 trials, axillary LN recurrence was observed in 1 patient, supraclavicular LN recurrence in 3 patients, and local and regional recurrence (location not specified) in 1 patient in the BCS + RT + tamoxifen group (n = 390) [8]. Data from the Memorial Sloan Kettering Cancer Center showed that axillary LN recurrence was observed in 7 patients, supraclavicular LN recurrence in 2 patients, and internal mammary LN recurrence in 1 patient, among a total of 2,326 patients [9]. In the current study, regional recurrence was observed in only 3 patients among 339 patients, but these patients did not receive regional RT initially. As the 5-year LRR rate was 7.3% in patients with a RS > 25 and 88% of these patients received standard chemotherapy, these findings suggest that more comprehensive regional RT might be considered for these patients.

In the current study, the surgical resection margin was involved in 18 patients (15 with invasive carcinoma and 3 with intraductal carcinoma), but all of them were free of LRR. The surgical resection margin is among the most important prognostic factors for LRR. However, 8 of these patients had involvement of the superficial or deep margin, which is known to have a lesser impact on LRR [17]. In addition, 10 of these patients received a higher dose of tumor bed boost (12.5–15 Gy in 3–6 fractions), which might contribute to the increased local control, although such a dose-response relationship was not observed in a previous randomized controlled trial [18].

The present study includes the typical shortcomings associated with a retrospective study design, such as selection bias. In addition, as LRR was observed in only 4 patients, risk factors such as surgical resection margin could not be analyzed further. Moreover, the follow-up period was relatively short considering the indolent course of node-negative, hormone receptor-positive breast cancer. Hence, further studies with a larger population and long-term follow-up are warranted to validate the findings of the current study.

In conclusion, excellent locoregional control was achieved in patients with node-negative, hormone receptor-positive/HER2-negative breast cancer who underwent BCS plus RT—including risk-adapted systemic therapy—according to the Oncotype DX RS. As regional recurrence was observed only in patients with a RS > 25 who were treated with only breast RT, regional RT might be considered for those patients with a high RS.

REFERENCES

1. Whelan TJ, Olivetto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015;373:307-16.  
2. Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015;373:317-27.
3. National Comprehensive Cancer Network. Breast cancer (version 3.2020). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed March 20th, 2020.

4. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707-16.

5. Sjöström M, Chang SL, Fishbane N, Davicioni E, Zhao SG, Hartman L, et al. Clinogenicomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer. J Clin Oncol 2019;37:3340-9.

6. Tramm T, Mohammed H, Myhre S, Kyndi M, Alsnor J, Børresen-Dale AL, et al. Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG82bc cohort. Clin Cancer Res 2014;20:5272-80.

7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.

8. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677-83.

9. Turashvili G, Chou JF, Brogi E, Morrow M, Dickler M, Norton L, et al. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2017;166:69-76.

10. Jegaddeesh NK, Kim S, Prabhu RS, Oprea GM, Yu DS, Godette KG, et al. The 21-gene recurrence score and locoregional recurrence in breast cancer patients. Ann Surg Oncol 2015;22:1088-94.

11. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111-21.

12. Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, et al. Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer. JAMA Oncol 2020;6:505-11.

13. Goodman CR, Seagle BL, Kocherginsky M, Donnelly ED, Shahabi S, Strauss JB. 21-gene recurrence score assay predicts benefit of post-mastectomy radiotherapy in T1-2NI breast cancer. Clin Cancer Res 2018;24:3678-87.

14. Jayasekera J, Schechter CB, Sparano JA, Jagsi R, White J, Chapman JW, et al. Effect of radiotherapy in early-stage, low-recurrence risk, hormone-sensitive breast cancer. J Natl Cancer Inst 2018;110:1370-9.

15. ClinicalTrials.gov. The IDEA study (individualized decisions for endocrine therapy alone). https://clinicaltrials.gov/ct2/show/NCT02400190. Accessed March 20th, 2020.

16. Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, et al. 21-gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst 2017;109:djw259.

17. Yoon TI, Lee JH, Lee SB, Sohn G, Kim J, Chung JY, et al. No association of positive superficial and/or deep margins with local recurrence in invasive breast cancer treated with breast-conserving surgery. Cancer Res Treat 2018;50:275-82.

18. Poortmans PM, Collette L, Horiot JC, Van den Broeck WF, Fourquet A, Kuten A, et al. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol 2009;90:80-5.